Bristol Myers Squibb Company $BMY Holdings Trimmed by Pzena Investment Management LLC

Key Points

• Pzena Investment Management trimmed its Bristol Myers Squibb stake by 0.5%, selling 88,687 shares, but still held 17.0 million shares worth approximately $980 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb beat quarterly expectations with $2.04 in adjusted EPS and $12.97 billion in revenue, up 5.7% year over year. The company also pays a quarterly dividend of $0.63 per share, yielding about 3.8% annually.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $66.06; JPMorgan and Truist recently raised their price targets to $73 and $70, respectively.

Pzena Investment Management LLC decreased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,007,044 shares of the biopharmaceutical company's stock after selling 88,687 shares during the period. Bristol Myers Squibb accounts for 2.9% of Pzena Investment Management LLC's investment portfolio, making the stock its 8th biggest holding. Pzena Investment Management LLC owned 0.83% of Bristol Myers Squibb worth $979,946,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of BMY. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 202 shares during the period. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the second quarter worth $25,000. Bayban purchased a new position in Bristol Myers Squibb in the fourth quarter worth $31,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at $32,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $66.07 on Wednesday. The company has a market capitalization of $134.97 billion, a P/E ratio of 14.55, a P/E/G ratio of 0.17 and a beta of 0.22. The business has a fifty day simple moving average of $59.94 and a two-hundred day simple moving average of $59.14. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.10.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. During the same quarter in the prior year, the firm earned $1.46 EPS. The business's revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Analyst Ratings Changes

BMY has been the subject of several research analyst reports. BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an "overweight" rating on the stock. Truist Financial restated a "buy" rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. JPMorgan Chase & Co. lifted their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Finally, Weiss Ratings upgraded shares of Bristol Myers Squibb from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source